N4 Pharma PLC (LON:N4P) announced its quarterly earnings results on Monday. The company reported GBX (2.60) (($0.04)) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. The company had revenue of GBX 200 million for the quarter. N4 Pharma PLC had a net margin of 1.05% and a return on equity of 1.54%.

N4 Pharma PLC (N4P) opened at 5.62 on Monday. N4 Pharma PLC has a 52 week low of GBX 1.20 and a 52 week high of GBX 12.50. The company’s market cap is GBX 4.20 million. The stock has a 50 day moving average of GBX 5.87 and a 200 day moving average of GBX 6.78.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/25/n4-pharma-plc-n4p-posts-earnings-results.html.

Separately, Beaufort Securities reiterated a “speculative buy” rating on shares of N4 Pharma PLC in a research note on Thursday, July 27th.

N4 Pharma PLC Company Profile

N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.

Receive News & Ratings for N4 Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.